The advance purchase agreement will allow EU member states to secure up to 200 million additional doses, the company said.

Johnson & Johnson is developing and testing Janssen's COVID-19 vaccine candidate via a multicountry single-dose phase III trial that started in September; a second phase III study with a two-dose protocol will start later this year. The vaccine includes Janssen's AdVac technology, which it also used to develop an Ebola vaccine and is the basis for that firm's HIV, RSV, and Zika vaccine candidates.

The company also plans to set aside up to 500 million vaccine doses for lower income countries, with delivery in mid-2021 following regulatory approval, it said.

FDA issues guidance on submitting EUA requests for COVID-19 vaccines
The U.S. Food and Drug Administration (FDA) on October 6 issued a new guidance with recommendations for developers of COVID-19 vaccines regarding the...

Centaur Biopharma to manufacture COVID-19 vaccine for Vaxart
Centaur Biopharmaceutical Services has expanded its manufacturing agreement with Vaxart to manufacture Vaxart's oral COVID-19 vaccine.

EMA to review BioNTech, Pfizer's SARS-CoV-2 vaccine
The European Medicines Agency (EMA) has accepted rolling review of BioNTech and Pfizer's SARS-CoV-2 vaccine candidate BNT162b2 based on preclinical and...

J&J reports positive preclinical results for COVID-19 vaccine
Johnson & Johnson reported that its lead COVID-19 vaccine candidate protected against SARS-CoV-2 in preclinical studies.

J&J announces manufacturing collaboration for COVID-19 vaccine
Johnson & Johnson, a Janssen Pharmaceuticals company, announced on April 24 a collaboration with Emergent BioSolutions to support the manufacturing...